Abstract
Introduction Projecting disease spread is challenging because of the heterogeneous nature of human interactions, including both natural societal interactions and how they change in response to pandemics. Simulations can provide important guidance regarding the likely impact of interventions on an assumed base case.
Methods This paper uses assumptions based on the COVID-19 pandemic to construct a Susceptible-Infectious-Recovered model representative of US society, focusing on the interrelationships of groups with differing contact networks (essential/non-essential workers and urban/non-urban populations). The model is used to explore the impact of interventions (reduced interactions, vaccinations and selective isolation) on overall and group-specific disease spread.
Results In the absence of herd immunity, temporary interventions will only reduce the overall number of disease cases moderately and spread them over a greater period of time unless they virtually eliminate disease and no new infections occur from exogenous sources. Vaccinations can provide stronger benefit, but can be limited by efficacy and utilization rates.
Conclusions While a highly effective and broadly utilized vaccine might halt disease spread, some combination of increased long-term surveillance and selective isolation of the most vulnerable populations might be necessary to minimize morbidity and mortality if only moderately effective vaccines are available.
Competing Interest Statement
Daniel Mytelka is a former employee of Eli Lilly and MIT and a former shareholder of Eli Lilly. These relationships terminated before the conception of this work.
Funding Statement
There was no external funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Modeling outputs referred to in the paper are available upon request.
